Drug Development Workshop: From Molecules to Marketplace
Date: Wednesday 28th February 2024
Time: 9.30am-12.00pm
Venue: 16 Mill Lane, Cambridge
This event run by Cambridge Academy of Therapeutic Sciences is open to PhD students, early career researchers and principal investigators from the University of Cambridge.
In this workshop, Dr Claire Thompson, CEO of Agility Life Sciences and University of Cambridge Expert in Residence, will guide participants through the complicated process of drug development. During the workshop, Claire will delve into the journey from the lab bench to the patient, discussing the process from initial conception to clinical trials, regulatory compliance and acquisition or commercialization. Attendees will have opportunities to work in groups to discuss the translation and development process in general as well as bring specific questions to Claire relating to their own research.
CATS-Milner Therapeutic Perspectives Series
The CATS-Milner Therapeutic Perspectives Series has recently been launched. The aim of this regular series is to bring together experts from a number of separate but closely linked sectors, to discuss the potentials and challenges within translational research and how we as an ecosystem can work together to create the right environment to support new treatments for patients. The series is aimed at a mixed academic-industry audience and draws on expert speakers from across academia, industry, medicine, investors, policy and funding.
The series is a joint venture between the Cambridge Academy of Therapeutic Sciences and the Milner Therapeutics Institute, two teams at the University who work across the traditional boundaries between disciplines and between academia and industry to facilitate and transform pioneering research into new therapies as well as support the education and training of the next generation of world-leading researchers. If you would like to connect, please look at the websites or get in touch via email.
Details of previous events in the series can be found below; please note that these events take place live and are not recorded.
If you have questions about this series or would like to join our email list for event updates, please email cats@admin.cam.ac.uk
Thursday January 13th 2022
Drug repurposing: the main challenges and solutions to fulfilling its potential
Our next event will focus on the potentials and challenges in drug repurposing. The panel will look at recent repurposing success stories before discussing the extraordinary potential artificial intelligence and machine learning approaches hold to impact repurposing, as well as some of the evolving regulatory and commercial considerations and barriers which need to be overcome.
Chair: Dr Neil Thompson – Chief Scientific Officer, Healx
Panel:
Dr Charlotte Summers: Reader in Intensive Care Medicine, University of Cambridge
Fiona Law: Partner – Patent Attorney, Potter Clarkson LLP
Dr Namshik Han: Head of Computational Research & AI, Milner Therapeutics Institute
Dr Catriona Crombie: Associate Director, Technology Transfer and Philanthropic Fund, LifeArc
What are the opportunities and challenges of the new technologies providing human model systems for drug discovery?
Panel:
Professor Kourosh Saeb-Parsy - Department of Surgery, University of Cambridge; CEO, Avatrial
Dr Cathy Vickers – Head of Innovation, NC3Rs
Professor Róisín Owens - Department of Chemical Engineering & Biotechnology, University of Cambridge
Dr Victoria March Durban – Chief Operating Officer, Cellesce
How can we make clinically meaningful progress in microbiome-related therapeutics development?
Panel:
Dr Kiran Patil – MRC Toxicology Unit Programme Lead, University of Cambridge
Professor Denise Kelly – Investment Advisor, Seventure Partners
Professor Julian Marchesi – Professor of Digestive Health, Imperial College London
Dr Kristin Wannerberger – Director R&D Alliance Management, Ferring Pharmaceuticals
Professor Fergus Shanahan – Professor and Chair of the Department of Medicine, University College Cork
Translating breakthroughs in Alzheimer’s Disease into new treatments
10th June 2021
Chair: John Skidmore, Chief Scientific Officer, ALBORADA Drug Discovery Institute, funded by Alzheimer’s Research UK
Panel:
David Rubinsztein, Cambridge Institute for Medical Research, University of Cambridge
James Rowe, MRC Cognition and Brain Sciences Unit, Department of Clinical Neurosciences, University of Cambridge
Susan Kohlhaas, Director of Research, Alzheimer’s Research UK
Peter Larsen, J&J Innovation
